January 1, 2026 — The slate is clean. All is forgiven. We have a fresh new year ahead. So that has us thinking about the trends that are likely to define 2026 in obesity, nutrition, and health. Here are five that floated to the top of our mind. 1. Healthy Weight for Life We have said it before. Weight […]
November 26, 2025 — It seems like some good news is overdue for Novo Nordisk. So the topline report of a phase two study with amycretin that looks like a plausible win is especially welcome. The results at hand come from a 36-week placebo controlled study with a wide range of oral and injection doses in persons with type […]
August 18, 2025 — We have a flourishing market for new obesity drugs. But that market has a problem. New drug developers are stumbling over what to target with their drugs. The old way of looking at goals for new drugs in this space was to aim for greater weight loss. More is better – right? In a new […]
July 21, 2025 — It’s no secret that Novo Nordisk is in something of a funk. In the last year, the value of the company has dropped by half. Its respected leader, Lars Fruergaard Jørgensen, stepped down suddenly in May. Lilly has taken the lead in the obesity market from semaglutide with its own tirzepatide, and numerous competitors are […]
June 26, 2025 — Stepping back from the intense swirl of obesity care research at the ADA meeting just concluded, one thing stands out: People are having a very hard time following the thread of all this innovation. If you have any doubt, just scan the reports of investment analysts at the meeting. On one hand, they know they […]
June 23, 2025 — With two new publications in the New England Journal of Medicine, we are thinking that CagriSema has something to teach us about using weight loss outcomes to judge the merits of a new obesity medicine. Is more always better? Researchers presented the data from these two pivotal clinical trials on CagriSema at the ADA Scientific […]
June 22, 2025 — We are only halfway through ADA2025 in Chicago and already the flood of information about new drugs for obesity like orforglipron, amycretin, and a host of others leaves us feeling like we have been sprayed down by a fire hose. Much more will be coming at us in the next two days. Orforglipron and Other […]
June 20, 2025 — We are landing in Chicago for the ADA Scientific Sessions and you can be sure that a veritable river of news about obesity will be flowing. Everything from basic science to innovative treatment and pragmatic approaches for clinical care and policy will be offered up by this meeting of the American Diabetes Association. This promises […]
March 11, 2025 — Drug development is tricky. If you want evidence for just how tricky it is, a quick look at the experience with CagriSema will give you a pretty good idea. Yesterday, Novo Nordisk announced topline results of this drug from their REDEFINE 2 clinical trial. Their press release talked about “superior results” for people with overweight […]
February 27, 2025 — More than a decade ago, targeting amylin receptors for treating obesity looked like hot opportunity. Amylin, a peptide hormone co-secreted with insulin by pancreatic beta cells, plays a role in regulating satiety and food intake. An amylin analog, pramlintide, gained FDA approval for treating diabetes. But efforts to develop it for treating obesity never quite […]
